Therapy Areas: AIDS & HIV
Moderna's COVID-19 vaccine approved by Singapore Health Sciences Authority for interim use
4 February 2021 -

Biotechnology company Moderna Inc (Nasdaq:MRNA) reported on Wednesday the receipt of the interim authorization of its mRNA vaccine against COVID-19 from Singapore Health Sciences Authority (HSA) under the Pandemic Special Access Route (PSAR).

The Singapore Ministry of Health's authorization of the COVID-19 vaccine is based on the totality of the company's scientific evidence, including a data analysis from the pivotal Phase 3 clinical study announced on 30 November 2020.

Additionally, the company has received authorization for its COVID-19 vaccine from health agencies in the US, Canada, Israel, the EU, the UK and Switzerland. Additional authorizations are currently under review in other countries and by the World Health Organization.

In addition, the Moderna COVID-19 vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein co-developed with the National Institute of Allergy and Infectious Disease's (NIAID) Vaccine Research Center. The first clinical batch was completed on 7 February 2020 and underwent analytical testing. The first participant in the NIAID-led Phase 1 study of the Moderna COVID-19 Vaccine was dosed on 16 March 2020. On 12 May 2020, the US FDA granted the the vaccine Fast Track designation.

Login
Username:

Password: